WNT-activated medulloblastoma: lines of therapy
4 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Non-metastatic, standard therapy | Maximal safe resection, 23.4 Gy craniospinal radiotherapy with tumour-bed boost (protons where available), then cisplatin, vincristine and cyclophosphamide or lomustine. | NCI PDQ: Childhood Medulloblastoma and Other CNS Embryonal Tumors Treatment (health professional version) | 93 | |
| All comers | Non-metastatic, de-escalation trials | 15 Gy (SJMB12) or 18 Gy (ACNS1422) craniospinal radiotherapy with reduced boost and fewer chemotherapy cycles, judged against historical survival. | NCI PDQ: Childhood Medulloblastoma and Other CNS Embryonal Tumors Treatment (health professional version) | 81 | |
| All comers | Metastatic or residual disease | High-risk therapy: 36 Gy craniospinal radiotherapy with boost and intensified chemotherapy, as for other groups. | NCI PDQ: Childhood Medulloblastoma and Other CNS Embryonal Tumors Treatment (health professional version) | 93 |
Special situations
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| HR-positive | Survivorship | Neurocognitive, audiological, endocrine and second-tumour follow-up for life. | NCI PDQ: Childhood Medulloblastoma and Other CNS Embryonal Tumors Treatment (health professional version) | 58 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.